Summary:
Epstein–Barr virus (EBV)-associated lymphoproliferative disease (LPD) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT). Therefore, early diagnosis of EBV reactivation and pre-emptive therapy may be clinically useful. We report three patients who presented with an extremely high EBV load in peripheral blood mononuclear cells and plasma without evidence of EBV disease. Following pre-emptive therapy with a single dose of rituximab, a concordant decrease of EBV-genome copies and B lymphocytes was observed. In all three patients, no EBV-associated LPD occurred. We conclude that pre-emptive therapy with rituximab appears to be effective for prevention of EBV-associated LPD after HSCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Curtis RE, Travis L, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.
Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11: 113–116.
Meerbach A, Gruhn B, Egerer R et al. Semiquantitative PCR analysis of Epstein–Barr virus DNA in clinical samples of patients with EBV-associated diseases. J Med Virol 2001; 65: 348–357.
Gruhn B, Hongeng S, Yi H et al. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998; 12: 675–581.
Yang J, Tao Q, Flinn IW et al. Characterization of Epstein–Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055–4063.
Ifthikharuddin JJ, Mieles LA, Rosenblatt JD et al. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol 2000; 65: 171–173.
Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502–1505.
Benkerrou M, Jais JP, Leblond V et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137–3147.
van Esser JWJ, Niesters HGM, van der Holt B et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogeneic stem celltransplantation. Blood 2002; 99: 4364–4369.
van der Kolk LE, Baars JW, Prins MH et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 2257–2259.
Acknowledgements
We greatly appreciate the information retrieval and data analysis services of Isabella Schiller and Ilona Wolf. The excellent technical assistance of Doris Glaser and Sabine Becker is gratefully acknowledged. The nurses and physicians of the Bone Marrow Transplant Unit are thanked for their conscientious care of patients and their dedicated assistance in obtaining patient samples.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gruhn, B., Meerbach, A., Häfer, R. et al. Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 31, 1023–1025 (2003). https://doi.org/10.1038/sj.bmt.1704061
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704061